Trang Vu
About Trang Vu
Trang Vu is a Scientist II at CytomX Therapeutics, specializing in in vivo studies of therapeutic monoclonal antibodies. With a background in biotechnology and a PhD in biochemistry and molecular biology, Vu has extensive experience in protein engineering and kinetic analysis of antibody interactions.
Current Role at CytomX Therapeutics
Currently, Trang Vu serves as Scientist II at CytomX Therapeutics, a position held since 2021. In this role, she conducts in vivo studies to evaluate the protective efficacy of therapeutic monoclonal antibodies. Her work contributes to the development of innovative treatments in the field of immunotherapy. The position is based in South San Francisco, California.
Previous Experience at CytomX Therapeutics
Trang Vu previously worked at CytomX Therapeutics as Scientist I from 2020 to 2021 and as Senior Research Associate from 2019 to 2020. During her time in these roles, she gained valuable experience in the research and development of therapeutic proteins. Her contributions helped advance the company's mission in the biopharmaceutical sector.
Research Background at University of California, San Francisco
Before her tenure at CytomX Therapeutics, Trang Vu was a Postdoctoral Researcher at the University of California, San Francisco from 2016 to 2019. In this capacity, she engaged in advanced research projects that further developed her expertise in biochemistry and molecular biology.
Education and Expertise in Biotechnology
Trang Vu earned her Bachelor's degree in Biotechnology from Vietnam National University in Ho Chi Minh City from 2006 to 2010. She later pursued her Doctor of Philosophy (PhD) in Biochemistry and Molecular Biology at Ulsan College of Medicine, completing her studies from 2011 to 2016. Her academic background provides a strong foundation for her current research activities.
Specialized Skills in Therapeutic Protein Development
Trang Vu has developed expertise in in vitro selection techniques using bacterial and phage display systems. She specializes in the design, engineering, expression, purification, and characterization of therapeutic proteins and peptides. Additionally, she focuses on the kinetic analysis of antibody and antibody fragment interactions with antigens and peptides, which is crucial for the development of effective therapeutic agents.